GlassScriptPhysician profile
Vivek C Gupta
NPI 1508183211
$68,766.84
in general payments reported to CMS, 2019-2025
14 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.49 · 2022: $15K · 2023: $6,967 · 2024: $25K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Travel and Lodging: $5,696 · Food and Beverage: $2,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,592.24 |
| Travel and Lodging | $5,696.19 |
| Food and Beverage | $2,566.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $67,146.47 | 2022-2025 | Wegovy |
| Inspire Medical Systems, INC. | $1,064.15 | 2024-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $162.86 | 2024-2025 | Dupixent |
| Heartflow, INC. | $103.31 | 2025 | |
| Lilly USA, LLC | $82.41 | 2022-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $31.49 | 2019 | |
| Integra Lifesciences Corporation | $31.23 | 2024 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Currax Pharmaceuticals LLC | $28.35 | 2022-2024 | Contrave |
| Agile Therapeutics, INC. | $24.30 | 2024 | Twirla |
| Viatris Specialty LLC | $22.48 | 2025 | Yupelri |
| Itamar Medical INC | $20.77 | 2025 | Watchpatone |
| Abbvie INC. | $18.06 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.84 | 2025 | Caplyta |
| Chiesi USA, INC. | $15.12 | 2024 | Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.